Aurora Kinase A as a Biomarker for the Detection of Bladder Cancer

极光激酶 A 作为检测膀胱癌的生物标志物

• 批准号: 8468663
• 负责人: BOGDAN A CZERNIAK
• 金额: $ 36.35万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-06 至 2015-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8468663
• 关键词: Affect; Bedside Testings; Biological Markers; Biopsy; Bladder; Bladder Neoplasm; Cancer Detection; Cell physiology; Cessation of life; Clinical; Clinical Oncology; Cost Effective Management; Cystoscopy; Cytology; Detection; Development; Diagnosis; Diagnostic; Diagnostic Trial; Disease; Early Detection Research Network; Early Diagnosis; Early treatment; Frequencies; Funding; Goals; Grant; Healthcare; Hematuria; Human; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of urinary bladder; Modeling; Monitor; Nomograms; Occupations; Patients; Performance; Positioning Attribute; Prognostic Marker; Protocols documentation; Reproducibility; Role; Sampling; Sensitivity and Specificity; Survival Rate; Techniques; Testing; Treatment Effectiveness; United States; Urine; Validation; Western World; aurora-A kinase; base; clinical practice; clinically significant; commercialization; compare effectiveness; high risk; human STK6 protein; improved; men; minimally invasive; novel; patient population; public health relevance; tumor progression

DESCRIPTION (provided by applicant): The long-term objective of this project is to improve the detection of one of the common human cancers arising in the bladder by non-invasive voided urine-based tests. Bladder cancer is the 4th most common cancer in men and 5th most common overall with an approximately 68,800 new cases and 14,100 deaths from the disease in 2008 in the United States. It is estimated that nearly 300,000 patients are regularly monitored in the United States through a variety of non-invasive (urine) and minimally invasive (bladder barbotage, cystoscopy, and biopsy) techniques. Therefore, the development of novel biomarkers that can detect bladder tumors by a non-invasive approach is of major clinical significance. In this grant we propose to validate aurora A FISH test as a biomarker for the detection of bladder cancer in the multi-institutional validation protocol. In this protocol, we will compare the specificity and sensitivity of aurora A FISH test with other known noninvasive bladder cancer detection tests for voided urine sediments such as urine cytology and commercially available multi-chromosomal FISH kit known as UroVysion, and NMP22 point-of-care test. The specific aims for this proposal are as follows: Specific Aim 1: Determine the reproducibility of the Aurora A FISH test. Specific Aim 2: Validate a model for BC detection in patients with hematuria and determine if Aurora A FISH and/or UroVysion FISH improves the model. A previously described nomogram incorporating clinical variables and NMP22 will be validated. Furthermore, the Aurora A FISH and UroVysion FISH tests will be assessed for their ability to improve the current nomogram. Specific Aim 3: Determine the ability of Aurora A FISH to detect BC and determine its performance with cytology, UroVysion FISH, and NMP22. The sensitivity and specificity of Aurora A FISH will be determined. The performance of Aurora A FISH will be compared with cytology, UroVysion FISH as well as NMP22 and the ability of a combination of markers to improve detection will be explored. Specific Aim 4: Determine the ability of Aurora A FISH to detect patients with BC who are at high risk of tumor progression. Aurora A FISH performance will be compared with that of cytology, UroVysion FISH, and NMP22.

描述（由申请人提供）：该项目的长期目标是通过非侵入性尿液检测来提高对膀胱中常见人类癌症之一的检测。膀胱癌是男性第四大最常见癌症，也是第五大最常见癌症，2008 年美国约有 68,800 例新发病例和 14,100 例死亡。据估计，美国有近 300,000 名患者通过各种无创（尿液）和微创（膀胱倒刺术、膀胱镜检查和活检）技术接受定期监测。因此，开发能够通过非侵入性方法检测膀胱肿瘤的新型生物标志物具有重要的临床意义。在这笔资助中，我们建议在多机构验证方案中验证极光 A FISH 测试作为检测膀胱癌的生物标志物。在本协议中，我们将比较 aurora A FISH 测试与其他已知的无创性膀胱癌检测测试的尿沉渣检测测试的特异性和敏感性，例如尿细胞学和市售多染色体 FISH 试剂盒（称为 UroVysion）和 NMP22 护理点测试。该提案的具体目标如下： 具体目标 1：确定 Aurora A FISH 测试的重现性。具体目标 2：验证血尿患者 BC 检测模型，并确定 Aurora A FISH 和/或 UroVysion FISH 是否改进了模型。先前描述的包含临床变量和 NMP22 的列线图将得到验证。此外，还将评估 Aurora A FISH 和 UroVysion FISH 测试改善当前列线图的能力。具体目标 3：确定 Aurora A FISH 检测 BC 的能力，并通过细胞学、UroVysion FISH 和 NMP22 确定其性能。 Aurora A FISH 的敏感性和特异性将被确定。 Aurora A FISH 的性能将与细胞学、UroVysion FISH 以及 NMP22 进行比较，并将探索标记物组合改善检测的能力。具体目标 4：确定 Aurora A FISH 检测肿瘤进展高风险的 BC 患者的能力。 Aurora A FISH 性能将与细胞学、UroVysion FISH 和 NMP22 的性能进行比较。